INN Approved by WHO

Global Phase 3 Clinical Trials Progressing Smoothly

AbClon, a company specializing in antibody drug development, announced on the 23rd that the International Nonproprietary Name (INN) for its HER2-targeted antibody drug candidate 'AC101', which was licensed to Shanghai Henlius Biotech in China, has been officially designated as 'dulpatatug' by the World Health Organization (WHO).


AbClon Confirms Official Name 'Dulpatatug' for Innovative Anticancer Drug 'AC101' View original image

Currently, dulpatatug is undergoing large-scale global Phase 3 clinical trials for metastatic gastric cancer, with more than 40% of dosing completed in major countries including the United States, China, Europe, Japan, Korea, and South America.


The newly confirmed ingredient name reflects the drug's unique mechanism of action and scalability. The prefix 'dul-' signifies the powerful synergistic effect of binding to a different HER2 domain than the standard treatment Herceptin, thereby achieving dual receptor blockade. The middle syllable '-ta-' indicates that it is an anticancer antibody that precisely targets cancer cells. Notably, the suffix '-tug' denotes an unmodified standard full-length antibody structure, which provides high stability. This allows for use not only in monotherapy and combination therapy but also as a backbone antibody for future next-generation innovative technologies such as antibody-drug conjugates (ADC).


According to the 'ASCO 2025' presentation, which reported two-year follow-up results from Phase 2 clinical trials in gastric cancer patients, dulpatatug reduced the risk of disease progression and death by approximately 80% compared to existing standard treatments. The company explained that this significantly outperformed the control group, clearly demonstrating the potential of dulpatatug as a best-in-class drug in the first-line treatment market for HER2-positive gastric cancer.


Dulpatatug is currently progressing smoothly through global Phase 3 trials directly comparing it with standard therapies as a first-line treatment for gastric cancer, while also accelerating strategies to expand its indications. For HER2 low-expression breast cancer, patient enrollment for Phase 2 trials has been completed and data analysis is underway. In addition, the combination Phase 2/3 trial of HER2-targeted ADC 'HLX87' with dulpatatug, targeting first-line breast cancer treatment, has administered the first patient dose.



A representative from AbClon stated, "Dulpatatug is a key asset that perfectly demonstrates our antibody development platform technology on the global stage. The confirmation of its ingredient name signals that commercialization is imminent. As our partner company aggressively advances Phase 3 clinical trials and expands the ADC pipeline, we expect mid- to long-term royalty income and corporate value to be further maximized."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing